1篇
您的检索式：作者名="Adam V.Patterson"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bioreductive prodrugs as cancer therapeutics:targeting tumor hypoxia显示文摘Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs. Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy. To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors. These hypoxia-activated prodrugs, including nitro compounds, N-oxides, quinones, and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygensensitive manner to form cytotoxins. Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clinical evaluation. In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs. We also describe the current knowledge of how each prodrug class is activated and detail the clinical progress of leading examples. | Christopher P.Guise Alexandra M.Mowday Amir Ashoorzadeh Ran Yuan Wan-Hua Lin Dong-Hai Wu Jeff B.Smaill Adam V.Patterson Ke Ding | 2014 | Chinese Journal of Cancer2014，33，2： | 9 |
您所在的机构暂未开通此部分的功能，请联系管理员